Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs

K. O. LEWIS, GEOFFREY NICHOLSON, P. LANCE, AND A. PATON

From the Departments of Clinical Chemistry and Clinical Investigation, Dudley Road Hospital, Birmingham B18 7QH, UK

SUMMARY The 14C-aminopyrine breath test was used to measure liver function in 14 normal subjects, 16 patients with alcoholic cirrhosis, 14 alcoholics without cirrhosis, and 29 patients taking a variety of drugs. The normal value for the breath test was 8.6 ± 1.5%, whereas it was significantly lower (5.1 ± 3.8%) in patients with alcoholic cirrhosis. Higher than normal values were found in some alcoholic patients without cirrhosis and in patients receiving enzyme-inducing drugs, such as phenobarbitone. There was a significant correlation between serum gamma-glutamyltransferase and breath test in these groups. Some patients with alcoholic cirrhosis may also be capable of enzyme induction.

The assessment of hepatic function by breath analysis after the oral administration of (dimethylamine-14C)-aminopyrine has been described by two groups (Hepner and Vesell, 1975; Bircher et al., 1976a; Lauterburg and Bircher, 1976). The test is based on the fact that aminopyrine is metabolised primarily in the liver with conversion of the 14C-labelled methyl groups to 14CO2 and that the concentration of 14CO2 in the breath is related to the rate of aminopyrine metabolism (Hepner and Vesell, 1974; Bircher et al., 1976b). It involves the oral administration of a trace dose of 14C-labelled aminopyrine and collection of a breath sample for analysis at two hours (Hepner and Vesell, 1975). Hepner found a highly significant correlation between the two-hour 14CO2 output and the aminopyrine metabolic clearance rate in control subjects and cirrhotic patients (Hepner and Vesell, 1974). We have used the test to assess liver function and, in particular, to assess the effects of alcohol and drugs on the liver.

Patients and methods

The following groups were studied:
1 16 patients with histologically confirmed alcoholic cirrhosis. Four of these were taking enzyme-inducing drugs (phenobarbitone, phenytoin).
2 20 alcoholics without clinical evidence of cirrhosis, attending an addiction unit. All had been drinking over 10 pints (about 6 litres) of beer or its equivalent daily for at least two years

and had been abstinent for less than two weeks (mean 7 ± 4 days) at the time of study. Liver biopsies in 19 were either normal or showed variable degrees of fatty change, portal inflammation or fibrosis. One patient refused biopsy.
3 28 patients on long-term drugs—barbiturates (11), corticosteroids (12), opiate addicts (5).
4 14 control subjects who were either healthy colleagues (7) or patients who did not have liver disease and were not taking drugs (7).

Informed consent was obtained from all those tested.

BREATH TEST TECHNIQUE (Hepner and Vesell, 1975) An oral dose of 1.5 μCi (dimethylamine-14C)-aminopyrine (Amersham, specific activity 12.2 mCi/mmol, 98% radiochemically pure) was given in water without previous fasting, and the subject was asked to rest quietly. Two hours later breath was collected by blowing through 4 ml of 10% hyamine hydroxide-ethanol in a glass scintillation vial until the thymol-phthalein indicator showed a sudden colour change from blue to colourless. This indicated that 2 mmol CO2 had been collected. After addition of scintillation cocktail the 14CO2 was counted and specific activity calculated. The cumulative excretion in the two-hour period was calculated by multiplying the specific activity by the endogenous output of carbon dioxide (ie, 9 mmol kg⁻¹ h⁻¹ (Winchell et al., 1970)) and expressed as a percentage of the administered dose.
Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs

SERUM ENZYMES

Serum gamma-glutamyltransferase EC2.3.2.2. (γ-GT) was assayed with the Boehringer kit using gamma-glutamyl p-nitranilide as substrate (normal range: < 40 IU/l); alkaline phosphatase by the Technicon SMA method using p-nitrophenylphosphate as substrate (normal range: 20-120 IU/l).

Results (Figs. 1 and 2)

The mean $^{14}$CO$_2$ excretion of the 16 patients with cirrhosis ($5.1 \pm 3.8\%$) was significantly lower than that ($8.6 \pm 1.5\%$) of the control group ($p > 0.01$) despite four cirrhotics who had values in the high normal range; these were the patients taking enzyme-inducing drugs. Four out of five patients with $^{14}$CO$_2$ excretion below 2.5\% died during the eight months of the study. The scatter of $^{14}$CO$_2$ excretion in 20 alcoholics without permanent liver damage was very wide but the mean value of $10.6 \pm 2.6\%$ was significantly above the mean control value ($p < 0.05$).

The mean figures for CO$_2$ excretion in patients taking barbiturates, corticosteroids, and opiates were respectively $15.2 \pm 4.0\%$, $11.6 \pm 1.4\%$, and $10.1 \pm 2.0\%$. These were significantly different from normal at levels of $p < 0.001$, $p < 0.01$, and $p < 0.05$ respectively.

There was a significant correlation between $^{14}$CO$_2$ excretion and serum γ-GT in patients taking barbiturates (Fig. 3) but not in those receiving corticosteroids. The number of opium addicts was too small to allow analysis.

Fig. 1 Two-hour $^{14}$CO$_2$ excretion as a percentage of the oral dose in normal subjects and in alcoholic liver disease (mean ± 1 SD).

Fig. 2 Two-hour $^{14}$CO$_2$ excretion as a percentage of the oral dose in patients on enzyme-inducing drugs (mean ± 1 SD).

Fig. 3 Relationship between breath test values and serum γ-GT levels for patients taking barbiturates.
Cirrhotic patients had raised serum alkaline phosphatase levels (mean 292 ± 219 IU/l) and greatly raised γ-GT (mean 283 ± 253 IU/l), and there was no correlation between γ-GT and 14CO2 excretion.

14CO2 excretion did not correlate with serum γ-GT in the non-cirrhotic alcoholic patients. When the four patients with alkaline phosphatase greater than 120 IU/l were excluded the mean values for alkaline phosphatase and γ-GT were 78 ± 19 and 139 ± 85 IU/l respectively, and there was a significant correlation between 14CO2 excretion and γ-GT (r = 0.50, p < 0.05).

Discussion

We have confirmed that, in general, patients with cirrhosis have a reduced 14CO2 excretion after 14C-aminopyrine administration. Moreover, the test may have some prognostic value, since the lowest values were found in patients who died of liver failure during the course of the study. It is cheap, easy to perform, non-invasive, and acceptable to patients. The dose of radiation is 0.5-2.5 mrem (comparable to a routine diagnostic chest radiograph), and repeated tests can be done in the same patient.

We had expected to find values intermediate between the normal and the cirrhotic groups (Hepner and Vesell, 1975) in alcoholics without permanent liver damage. Such patients, however, often had increased 14CO2 excretion and this correlated with the serum γ-GT level in those patients with normal serum alkaline phosphatase. Exclusion of the patients with raised total alkaline phosphatase removes those with an obstructive cause for a raised γ-GT (Ceriotti, 1976) but may not remove all such cases, for Brohult and Sundblad (1973) have demonstrated cholestasis in alcoholics with normal total alkaline phosphatase by the presence of alpha-I phosphatase isoenzyme in their serum. Prolonged consumption of alcohol increases hepatic mixed-function oxidase activity (Lieber, 1973), shortens the half-life of several drugs (Misra et al., 1971), and raises the serum γ-GT level even when other liver function tests are normal (Rosalki and Rau, 1972). It has been suggested (Rosalki, 1975) that the sensitivity of serum γ-GT to heavy alcohol consumption is in part due to γ-GT induction in the hepatic microsomes and also to hepatic microsomal injury by alcohol. The significant correlation between the breath test and serum γ-GT in patients taking barbiturates, which are known to cause up to three-fold increases in γ-GT, suggests that the increase in breath test values is due to enzyme induction, and this may also be the explanation for the findings in alcoholics without permanent liver damage.

Although several methods exist for the measurement of enzyme induction, none is entirely satisfactory (Neale, 1975). Nevertheless, we believe that the high 14CO2 excretion found in some of the patients may provide a pointer to enzyme induction. It is of considerable interest that the four patients with cirrhosis who had high values for 14CO2 excretion were all taking enzyme-inducing drugs, and this suggests that the diseased liver may still be capable of increasing its rate of drug metabolism (Levi et al., 1968).

We thank Dr M. I. Akhter for access to his patients at the Drug Addiction Unit.

References


Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs

Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs.

K O Lewis, G Nicholson, P Lance and A Paton

doi: 10.1136/jcp.30.11.1040

Updated information and services can be found at: http://jcp.bmj.com/content/30/11/1040

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/